Clinical Trial Diversity Action Plans Need Timely US FDA Feedback, Groups Say

Industry organizations argued feedback should be expected and object to draft guidance language suggesting it may be optional. The agency also should apply waiver criteria flexibly and address potential consequences if enrollment goals are not met, stakeholders say.

Diversity paper cutouts
Sponsors' clinical trial diversity action plans would benefit from FDA feedback, industry groups said. • Source: Shutterstock

The US Food and Drug Administration should provide timely feedback on biopharma sponsors’ clinical trial diversity action plans and explain its enforcement approach if goals are not met, industry and patient groups said.

Key Takeaways
  • The FDA should commit to reviewing and providing feedback on diversity action plan proposals within a certain timeframe, draft guidance comments state.

In comments on a June draft guidance on diversity action plans, stakeholders also asked the FDA to clarify the studies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Boosting EU Clinical Trials: EMA Opens Dialogue With Global CRO Group

 
• By 

The European Medicines Agency’s inaugural bilateral meeting with the Association of Clinical Research Organizations underscores ACRO’s commitment to advancing innovation and its presence in the EU clinical trials ecosystem.

Cancer Drug Combos: US FDA Guidance Offers Options Beyond Factorial Trials

 
• By 

Acknowledging the risks and limitations of factorial designs, draft guidance outlines how sponsors might employ external data, such as registries or patient-level real-world data, for combination cancer therapies.

US FDA Rare Disease Hub RISEs After Slow Start

 

The first “Rare disease Innovation, Science and Exploration (RISE) meeting to discuss the choice of control arms for studies in small populations will be Sept. 3 after plans were delayed by ongoing changes at the FDA.

GDPR Clarity For Pharma: Industry Code Nears EU-Wide Approval After Six-Year Journey

 
• By 

The pharmaceutical industry is edging closer to EU-wide clarity on how the bloc’s data privacy rules can be applied consistently to clinical trials and pharmacovigilance activities.

More from R&D

UK Initiative Steps Up Efforts To Tackle Recruitment Bottlenecks In Dementia Trials

 

A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.

New Advisory Group To Shape UK’s Simplified Informed Consent Process

 

Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access

Research Advances And Filings Prompt EMA To Revise Alzheimer’s Trial Guideline

 

Following EU approval of the first disease-modifying treatment for Alzheimer’s disease, and with a second expected soon, the European Medicines Agency plans to update its guidance to support the design of state-of-the-art clinical trials for the disease and enhance drug development.